FrancophonIA/ELRC3.0 huggingface dataset:
English: The most commonly reported liver-related adverse reactions included increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood bilirubin (see section 4.8).
Danish: De hyppigst indberettede leverrelaterede bivirkninger var stigning i alanin-aminotransferase (ALAT), aspartat-aminotransferase (ASAT) og plasma-bilirubin (se pkt.
English: Of the patients enrolled in this study, 389 patients (53.8%) had received one prior sunitinib-based therapy, 251 patients (34.7%) had received one prior cytokine-based therapy (interleukin-2 or interferon-alpha), 59 patients (8.2%) had received one prior bevacizumab-based therapy, and 24 patients (3.3%) had received one prior temsirolimus-based therapy.
Danish: I dette studie havde 389 af de inkluderede patienter (53,8%) tidligere fået sunitinibbaseret behandling, 251 patienter (34,7%) havde tidligere fået cytokinbaseret behandling (interleukin-2 eller interferonalfa), 59 patienter (8,2%) havde tidligere fået bevacizumabbaseret behandling og 24 (3,3%) patienter havde tidligere fået temsirolimusbaseret behandling.
English: The European Medicines Agency has waived the obligation to submit the results of studies with axitinib in all subsets of the paediatric population for treatment of kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney) (see section 4.2 for information on paediatric use).
Danish: Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med axitinib i alle undergrupper af den pædiatriske population til behandling af nyre- og nyrebækkenkarcinom (eksklusive nefroblastom, nefroblastomatose, clear-cell-sarkom, mesoblastisk nefrom, nyremarvskarcinom og rabdoid tumor i nyren) (se pkt.
English: Maximal induction with high-dose strong CYP3A4/5 inducers has been reported to occur within one week of treatment with the inducer.
Danish: Maksimal induktion med CYP3A4/5induktorer er set indenfor 1 uges behandling med induktoren.
English: e Including Leukoencephalopathy.
Danish: Inklusive leukoencefalopati
English: • phenytoin, carbamazepine or phenobarbital, anti-epileptics used to stop seizures or fits;
Danish: • phenytoin, carbamazepin og phenobarbital, epilepsimedicin til at standse krampeanfald
English: Rifampicin, a strong inducer of CYP3A4/5, administered at a dose of 600 mg once daily for 9 days, reduced the mean AUC by 79% and Cmax by 71% of a single 5 mg dose of axitinib in healthy volunteers.
Danish: Rifampicin, en potent induktor af CYP3A4/5, administreret i doser på 600 mg 1 gang dagligt i 9 dage, reducerede AUC med 79% og Cmax med 71% i forhold til 1 enkelt oral dosis på 5 mg hos raske forsøgspersoner.
English: The recommended dose is 5 mg twice a day.
Danish: Den sædvanlige dosis er 5 mg 2 gange daglig.
English: Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy.
Danish: Patienternes blodtryk skal kontrolleres og om nødvendigt behandles med standard antihypertensiv behandling.
English: CYP1A2 and CYP2C19 inhibitors
Danish: CYP1A2 og CYP2C19-hæmmere
English: In a controlled clinical study with axitinib for the treatment of patients with RCC, one patient inadvertently received a dose of 20 mg twice daily for 4 days and experienced dizziness (Grade 1).
Danish: I et klinisk studie med axitinib til behandling af patienter med RCC, fik 1 patient uforvarende en dosis på 20 mg 2 gange dagligt i 4 dage og oplevede svimmelhed (grad 1).
English: Swallow the tablets whole with water, with or without food.
Danish: Synk tabletten hel sammen med vand.
English: • The other ingredients are microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, hypromellose 2910 (15 mPa·s), titanium dioxide (E171), triacetin (E1518), iron oxide red (E172) (see section 2 Inlyta contains lactose (milk sugar)).
Danish: - Øvrige indholdsstoffer: mikrokrystallinsk cellulose, lactosemonohydrat, croscarmellosenatrium, magnesiumstearat, hypromellose 2910 (15 mPa·s), titandioxid (E171), triacetin E1518), rød jernoxid (E172) (se pkt.
English: Do not use any pack that is damaged or shows signs of tampering.
Danish: Brug ikke dette lægemiddel, hvis du bemærker at pakningen er ødelagt eller viser tegn på at have været åbnet.
English: ORR b,e % (95% CI)
Danish: % (95% CI)
English: After oral administration of axitinib tablets, the mean absolute bioavailability is 58% compared to intravenous administration.
Danish: Sammenlignet med intravenøs administration er den gennemsnitlige absolutte biotilgængelighed 58% efter oral administration af axitinib tabletter.
English: • Flatulence (wind), haemorrhoids, bleeding from gums, bleeding from the rectum, a burning or stinging sensation in the mouth
Danish: • Luft i maven, hæmorider, blødende gummer, blødning fra endetarmen, en brændende eller sviende fornemmelse i munden
English: Axitinib has not been studied in patients < 18 years of age.
Danish: Pædiatrisk population Axitinib er ikke undersøgt hos patienter under 18 år.
English: The following medicines may increase the risk of side effects with Inlyta:
Danish: Medicin nævnt herunder kan muligvis øge risikoen for bivirkninger af Inlyta:
English: h Including activated partial thromboplastin time prolonged, anal haemorrhage, arterial haemorrhage, blood urine present, central nervous system haemorrhage, cerebral haemorrhage, coagulation time prolonged, conjunctival haemorrhage, contusion, diarrhea haemorrhagic, dysfunctional uterine bleeding, epistaxis, gastric haemorrhage, gastrointestinal haemorrhage, gingival bleeding, haematemesis, haematochezia, haematocrit decreased, haematoma, haematuria, haemoglobin decreased, haemoptysis, haemorrhage, haemorrhage coronary artery, haemorrhage urinary tract, haemorrhoidal haemorrhage, haemostasis, increased tendency to bruise, international normalized ratio increased, lower gastrointestinal haemorrhage, melaena, petechiae, pharyngeal haemorrhage, prothrombin time prolonged, pulmonary haemorrhage, purpura, rectal haemorrhage, red blood cell count decreased, renal haemorrhage, scleral haemorrhage, scrotal haematocoele, splenic haemotoma, splinter haemorrhage, subarachnoid haemorrhage, tongue haemorrhage, upper gastrointestinal haemorrhage and vaginal haemorrhage.
Danish: Inklusive hjertesvigt, kronisk venstresidig hjerteinsufficiens, kardiopulmonalt svigt, nedsat uddrivningfraktion, venstre ventrikeldysfunktion og højre ventrikelsvigt Inklusive accelereret hypertension, blodtryksstigning, hypertension og hypertensiv krise Inklusive forlængelse af aktiveret partiel tromboplastin-tid, anal blødning, arteriel blødning, blod i urinen, blødning i centralnervesystemet, hjerneblødning, forlænget koagulationstid, konjunktival blødning, kontusion, hæmoragisk diarré, dysfunktionel uterinblødning, epistaxis, gastrisk blødning, gastrointestinal blødning, gingival blødning, hæmatemese, hæmatokesi, nedsat hæmatokrit, hæmatom, hæmaturi, nedsat hæmoglobin, hæmoptyse, blødning, blødning i koronararterie, blødning i urinvejen, hæmorideblødning, hæmostase, øget tendens til blå mærker, stigning i INR (international normalised ratio), nedre gastrointestinal blødning, melæna, petekkier, faryngealblødning, forlænget protrombintid, pulmonal blødning, purpura, rektalblødning, nedsat antal røde blodlegemer, renalblødning, skleralblødning, skrotal hæmatocele, milthæmatom, splinthæmoragi, subaraknoidalblødning, tungeblødning, øvre gastrointestinal blødning og vaginal blødning.
English: Prior cytokine treatment
Danish: Tidligere cytokinbehandling
English: Subsequently, using the same criteria, patients who tolerate an axitinib dose of 7 mg twice daily may have their dose increased to a maximum of 10 mg twice daily.
Danish: Efterfølgende kan patienter, som tåler axitinib 7 mg 2 gange dagligt, få øget deres dosis til højst 10 mg 2 gange dagligt ud fra de samme kriterier.
English: Inlyta is not recommended for people aged under 18.
Danish: Inlyta må ikke bruges til børn og unge under 18 år.
English: Routine laboratory assessments detected elevated haemoglobin above ULN in 9.7% of patients receiving axitinib.
Danish: Ved rutinemæssige laboratorieundersøgelser fandt man hæmoglobinniveauer over det normale hos 9,7% af patienterne i behandling med axitinib.
English: • Headache, taste disturbance or loss of taste
Danish: • Hovedpine, smagforstyrrelser eller manglende smagssans
English: Co-administration of axitinib with strong CYP3A4/5 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, erythromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin) may increase axitinib plasma concentrations.
Danish: Samtidig administration af axitinib og potente CYP3A4/5hæmmere (f.eks. ketoconazol, itraconazol, clarithromycin, erythromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir og telithromycin) kan øge plasmakoncentrationen af axitinib.
English: In a clinical dose finding study with axitinib, subjects who received starting doses of 10 mg twice daily or 20 mg twice daily experienced adverse reactions which included hypertension, seizures associated with hypertension, and fatal haemoptysis.
Danish: I et klinisk dosis-respons studie med axitinib observerede man hos forsøgspersoner, der modtog startdoser på 10 mg eller 20 mg 2 gange dagligt, bivirkninger omfattende hypertension, kramper i forbindelse med hypertension og dødelig hæmoptyse.
English: Elevation of haemoglobin or haematocrit
Danish: Stigning i hæmoglobin eller hæmatokrit
English: Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival.
Danish: Det er blevet vist, at axitinib er en potent hæmmer af endotelcellers proliferation og -overlevelse, der medieres via VEGF.
English: Your doctor should do blood tests to check your liver function before and during treatment with Inlyta.
Danish: Lægen vil tage blodprøver før og under behandlingen med Inlyta.
English: Therefore, coadministration of axitinib with CYP1A2 substrates may result in increased plasma concentrations of CYP1A2 substrates (e.g. theophylline).
Danish: Samtidig administration af axitinib og CYP1A2-substrater kan medføre en stigning i koncentrationen af CYP1A2-substrater (f.eks. teofyllin).
English: • Bleeding.
Danish: • Blødninger.
English: • Do not breast-feed during treatment with Inlyta.
Danish: • Du må ikke amme, mens du er i behandling med Inlyta.
English: In vitro studies of CYP and UGT inhibition and induction In vitro studies indicated that axitinib does not inhibit CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, or UGT1A1 at therapeutic plasma concentrations.
Danish: In vitro studier af CYP- og UGT-hæmning og -induktion In vitro studier antyder, at axitinib ikke hæmmer CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 eller UGT1A1 ved terapeutiske plasmakoncentrationer.
English: • Shortness of breath, cough, hoarseness
Danish: • Åndenød, hoste, hæshed
English: At the 5 mg twice daily dose in the fed state, the geometric mean peak plasma concentration and 24-hour AUC were 27.8 ng/mL and 265 ng.h/mL, respectively, in patients with advanced RCC.
Danish: Ved doseringen 5 mg 2 dagligt til ikke-fastende patienter med RCC er den gennemsnitlige peak-plasmakoncentration og 24-timers AUC henholdsvis 27,8 ng/ml og 265 ng.time/ml.
English: In vitro studies indicated that axitinib inhibits P-glycoprotein.
Danish: In vitro studier antyder, at axitinib hæmmer P-glykoprotein.
English: Caution should be exercised due to the risk of increased axitinib plasma concentrations in patients taking strong inhibitors of these isozymes.
Danish: Forsigtighed bør udvises, hos patienter der tager potente hæmmere af disse isoenzymer, på grund af risikoen for stigning i plasmakoncentrationen af axitinib.
English: h One-sided p-value from a log-rank test of treatment stratified by ECOG performance status.
Danish: Én-sidet p-værdi fra en log-rank test af behandling stratificeret efter ECOG performance status i.
English: CI = Confidence interval, HR = Hazard ratio (axitinib/sorafenib); ITT: Intent-to-treat; NE: not estimable; NS:
Danish: CI = Confidence interval; HR=Hazard ratio (axitinib/sorafenib); IE: Ikke estimerbart; IS: Ikke significant; ITT: Intent-to-treat; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival a.
English: Partially reversible dental caries were observed in mice treated for more than 1 month at exposure levels similar to the expected human exposure.
Danish: Delvis reversibel dentalcaries ses hos mus behandlet i mere end 1 måned med doser svarende til human-terapeutiske doser.
English: The most common (≥ 20%) adverse reactions observed following treatment with axitinib were diarrhoea, hypertension, fatigue, decreased appetite, nausea, weight decreased, dysphonia, palmar-plantar erythrodysaesthesia (hand-foot) syndrome, haemorrhage, hypothyroidism, vomiting, proteinuria, cough, and constipation.
Danish: De hyppigste bivirkninger (>20%), som ses ved behandling med axitinib er diarré, hypertension, træthed, nedsat appetit, kvalme, vægttab, dysfoni, palmo-plantar erytrodysæstesi (hånd- og fodsyndrom), blødning, hypotyreose, opkastning, proteinuri, hoste og obstipation.
English: Findings in females included signs of delayed sexual maturity, reduced or absent corpora lutea, decreased uterine weights and uterine atrophy at exposures approximately equivalent to the expected human exposure.
Danish: Fund hos hunner omfatter tegn på forsinket seksuel modning, reduceret eller manglende corpora lutea, nedsat uterusvægt og uterinatrofi ved doser svarende til human-terapeutiske doser.
English: A dose decrease is recommended when administering axitinib to patients with moderate hepatic impairment (Child-Pugh class B) (e.g. the starting dose should be reduced from 5 mg twice daily to 2 mg twice daily).
Danish: Det anbefales at nedsætte dosis ved behandling af patienter med moderat nedsat leverfunktion (ChildPugh klasse B) (f.eks. fra startdosis på 5 mg 2 gange dagligt til 2 mg 2 gange dagligt).
English: Pregnant mice exposed to axitinib showed an increased occurrence of cleft palate malformations and skeletal variations, including delayed ossification, at exposure levels below the expected human exposure.
Danish: Drægtige mus eksponeret for axitinib udviste stigning i ganespalte og skeletforandringer, herunder forsinket ossifikation ved doser under human-terapeutiske doser.
English: In a clinical dose-finding study, concurrent elevations of ALT (12 times the ULN) and bilirubin (2.3 times the ULN), considered to be drug-related hepatotoxicity, were observed in 1 patient who received axitinib at a starting dose of 20 mg twice daily (4 times the recommended starting dose).
Danish: I et klinisk dosis-respons studie sås en samtidig stigning af ALAT (12 gange [ULN]) og bilirubin (2,3 gange ULN), vurderet til at være lægemiddelrelateret levertoksicitet, hos 1 patient ved en startdosis på 20 mg 2 gange dagligt (4 gangeden anbefalede daglige dosis).
English: Arterial embolic and thrombotic events
Danish: Arterielle emboliske og trombotiske hændelser
English: If you forget to take Inlyta
Danish: Hvis du har glemt at tage Inlyta
English: The following medicines may reduce the effectiveness of Inlyta:
Danish: Medicin nævnt herunder kan muligvis nedsætte virkningen af Inlyta:
English: Tell your doctor if you have severe abdominal pain.
Danish: Fortæl lægen, hvis du får voldsomme mavesmerter.
English: Kaplan-Meier curve of progression-free survival by independent assessment for the overall population
Danish: Figur 1 Kaplan-Meier kurve over progressionsfri overlevelse udfra uafhængig vurdering i den samlede population.
English: No dosage adjustment is required on the basis of patient age or race (see sections 4.2 and 5.2).
Danish: Dosisjustering på grund af alder eller race er ikke nødvendig (se pkt.
English: Tell your doctor if you get tired more easily, generally feel colder than other people, or your voice deepens whilst taking this medicine.
Danish: Fortæl det til lægen, hvis du hurtigt bliver træt, føler dig kuldskær eller hvis din stemme bliver dybere, mens du tager Inlyta.
English: If you stop taking Inlyta
Danish: Hvis du holder op med at tage Inlyta
English: Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Danish: Bør ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form af hereditær lactasemangel (Lapp Lactase deficiency) eller glucose/galactosemalabsorption.
English: The recommended dose of axitinib is 5 mg twice daily.
Danish: Dosering Den anbefalede dosis er 5 mg axitinib 2 gange dagligt.
English: • The active substance is axitinib.
Danish: - Aktivt stof: axitinib.
English: If you vomit while taking Inlyta
Danish: Hvis du kaster op, mens du tager Inlyta
English: Therefore co-administration of axitinib is not expected to reduce the plasma concentration of co-administered CYP1A1, CYP1A2, or CYP3A4/5 substrates in vivo.
Danish: Samtidig administration af axitinib forventes ikke at reducere plasmakoncentrationen af CYP1A1, CYP1A2 eller CYP3A4/5 substrater in vivo.
English: • Hole in the stomach or intestine or formation of fistula (abnormal tube-like passage from one normal body cavity to another body cavity or the skin).
Danish: • Hul i mavesæk eller tarm eller fistel-dannelse (unormal rør-lignende passage fra et hulrum i kroppen til et andet eller til huden).
English: Figure 2.
Danish: Skema 2.
English: 56 tablets
Danish: 60 tabletter
English: The decision to resume axitinib therapy after surgery should be based on clinical judgment of adequate wound healing.
Danish: Beslutning om at genoptage behandlingen bør baseres på klinisk vurdering af tilfredsstillende sårheling.
English: Repeat dose toxicity
Danish: Gentagne dosistoksicitetsforsøg
English: • If during treatment with this medicine, you get symptoms such as headache, confusion, seizures (fits), or changes in vision with or without high blood pressure.
Danish: • Hvis du under behandlingen med Inlyta får symptomer såsom hovedpine, forvirring, kramper (krampeanfald) eller synsforstyrrelser med eller uden højt blodtryk.
English: Venous embolic and thrombotic events
Danish: Venøse emboliske og trombotiske hændelser
English: Axitinib should not be used during breast-feeding.
Danish: Axitinib må ikke anvendes under amning.
English: In a randomised, 2-way crossover study, 35 healthy subjects were administered a single oral dose of axitinib (5 mg) in the absence and presence of 400 mg ketoconazole for 7 days.
Danish: I et randomiseret overkrydsningsforsøg, fik 35 raske forsøgspersoner en enkeltdosis axitinib (5 mg) med og uden samtidig dosering af 400 mg ketokonazol i 7 dage.
English: Thrombocytopenia Polycythaemiac
Danish: Anæmia Trombocytopeni Polycytæmi
English: In vitro studies in human hepatocytes also indicated that axitinib does not induce CYP1A1, CYP1A2, or CYP3A4/5.
Danish: In vitro studier med humane hepatocytter viste, at axitinib ikke inducerede CYP1A1, CYP1A2 eller CYP3A4/5.
English: The haemorrhagic adverse reactions in patients treated with axitinib included epistaxis (7.8%), haematuria (3.6%), haemoptysis (2.5%), rectal haemorrhage (2.2%), gingival bleeding (1.1%), gastric haemorrhage (0.6%), cerebral haemorrhage (0.3%) and lower gastrointestinal haemorrhage (0.3%).
Danish: Bivirkningerne hos patienter i behandling med axitinib inkluderede epistaxis (7,8%), hæmaturi (3,6%), hæmoptyse (2,5%), rektalblødning (2,2%), gingival blødning (1,1%), gastrisk blødning (0,6%), hjerneblødning (0,3%) og nedre gastrointestinal blødning (0,3%).
English: Based on the pharmacological properties of axitinib, it may cause foetal harm when administered to a pregnant woman.
Danish: Baseret på axitinibs farmakologiske egenskaber, kan axitinib være fosterskadende.
English: Very common Hypothyroidismc Common
Danish: Meget almindelig Hypotyreose Almindelig
English: Ketoconazole, a strong inhibitor of CYP3A4/5, administered at a dose of 400 mg once daily for 7 days, increased the mean area under the curve (AUC) 2-fold and Cmax 1.5-fold of a single 5-mg oral dose of axitinib in healthy volunteers.
Danish: Ketoconazol, en potent hæmmer af CYP3A4/5, administreret i doser på 400 mg 1 gang dagligt i 7 dage, øgede middelarealet under kurven (AUC) 2 gange og Cmax 1,5 gange i forhold til 1 enkelt oral dosis på 5 mg hos raske forsøgspersoner.
English: Axitinib is metabolised primarily in the liver by CYP3A4/5 and to a lesser extent by CYP1A2, CYP2C19, and UGT1A1.
Danish: Axitinib metaboliseres primært i leveren af CYP3A4/5 og i mindre grad af CYP1A2, CYP2C19 og UGT1A1.
English: It is important to check your blood pressure before you take this medicine, and regularly while you are taking it.
Danish: Det er vigtigt, at blodtrykket bliver målt inden behandlingen startes og regelmæssigt under behandlingen.
English: Inlyta is indicated for the treatment of advanced kidney cancer (advanced renal cell carcinoma) in adults, when another medicine (called sunitinib or a cytokine) is no longer stopping disease from progressing.
Danish: Inlyta er medicin, der bruges til behandling af fremskreden nyrekræft (fremskreden renalcellekræft) hos voksne, når anden medicin mod kræft (sunitinib eller et cytokin) ikke virker længere.
English: Within each system organ class, adverse reactions with the same frequency are presented in order of decreasing seriousness.
Danish: Bivirkninger med samme hyppighed er angivet i faldende orden indenfor hver organklasse.
English: Population pharmacokinetic analyses have shown that axitinib clearance was not altered in subjects with renal impairment and no dose adjustment of axitinib is required.
Danish: Farmakokinetiske populationsundersøgelser har vist, at axitinib-clearance ikke er påvirket hos patienter med nedsat nyrefunktion.
English: A risk ratio > 1 indicated a higher likelihood of responding in the axitinib arm; a risk ratio < 1 indicated a higher likelihood of responding in the sorafenib arm. g One-sided p-value from Cochran-Mantel-Haenszel test of treatment stratified by ECOG performance status and prior therapy.
Danish: En risiko-ratio >1 indikerer større sandsynlighed for response i axitinib-armen; En risiko-ratio <1 indikerer større sandsynlighed for response i sorafenib-armen.
English: c One-sided p-value from a log-rank test of treatment stratified by ECOG performance status and prior therapy.
Danish: Én-sidet p-værdi fra en log-rank test af behandling stratificeret efter ECOG performance status og tidligere behandling.
English: HDPE bottle with a silica gel desiccant and a polypropylene closure containing 180 film-coated tablets.
Danish: HDPE beholder med silicagel tørrekapsel og polypropylenlåg indeholdende 180 filmovertrukne tabletter.
English: Dosing of axitinib at 5 mg twice daily resulted in less than two-fold accumulation compared to administration of a single dose.
Danish: Akkumuleringen var mindre end det dobbelte ved indgift af 5 mg axitinib 2 gange dagligt sammenlignet med administration af 1 enkelt dosis.
English: b National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 c See Description of selected adverse reactions section.
Danish: Bivirkningerne er anført efter behandlingsrelateret hyppighed uanset årsag National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 Se beskrivelse af udvalgte bivirkninger i punktet herunder Dødelige tilfælde (Grad 5) er set
English: Prior sunitinib treatment
Danish: Tidligere sunitinibbehandling
English: Management of cardiac failure events may require temporary interruption or permanent discontinuation and/or dose reduction of axitinib therapy.
Danish: Håndtering af hjertesvigt kan kræve midlertidig eller permanent afbrydelse af behandlingen og/eller dosisnedsættelse af axitinib.
English: Thyroid stimulating hormone (TSH) increased was reported as an adverse reaction in 5.3% of patients receiving axitinib.
Danish: Stigning i thyreoidea-stimulerende hormon (TSH) blev set som bivirkning hos 5,3% af patienterne i behandling med axitinib.